The chemical class known as p130 inhibitors belongs to a group of compounds that exhibit a specific mode of molecular action, targeting the p130 protein. P130 is a critical regulator of cellular processes, primarily involved in cell cycle control, cellular proliferation, and differentiation. This class of inhibitors operates by modulating the activity or function of the p130 protein, thereby influencing downstream cellular responses. The p130 protein is a member of the retinoblastoma (Rb) family of tumor suppressor proteins, which play a pivotal role in maintaining the balance between cell division and growth arrest. P130 inhibitors are designed to interact with various molecular components within the cellular machinery that regulate p130's activity. By binding to specific sites on the p130 protein or its associated partners, these inhibitors disrupt the intricate signaling pathways that govern cell cycle progression.
Through this disruption, p130 inhibitors can potentially halt or slow down the cell cycle, which is crucial for preventing uncontrolled cell division and the development of various pathological conditions. The structural features of these inhibitors are carefully engineered to enable selective and potent interactions with the p130 protein, ensuring minimal off-target effects on other cellular processes. Research into p130 inhibitors has provided valuable insights into the intricate network of cellular mechanisms that underlie cell cycle control and proliferation. By uncovering the molecular interactions between p130 and its binding partners, scientists aim to develop a deeper understanding of how aberrations in these interactions can contribute to disease development.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 0332991 Isethionate | 827022-33-3 | sc-478943 | 1 mg | $300.00 | ||
Palbociclib is an agent in research used to inhibit cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in cell cycle regulation. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib works by slowing down cell division through the targeting of specific enzymes in the cell cycle. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4/6 inhibitor studied in the research of advanced or metastatic breast cancer. It helps control cancer progression by inhibiting specific cell cycle proteins. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
P276-00 is an experimental CDK inhibitor with potential anticancer properties. It targets various CDKs, including CDK1, CDK2, CDK4, and CDK9, to interfere with the growth of cancer cells. | ||||||
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine Methanesulfonate | 1231930-82-7 | sc-496536 | 2.5 mg | $398.00 | ||
LY2835219 is a CDK4/6 inhibitor under investigation for its effectiveness in cancer therapy. It disrupts specific proteins to halt uncontrolled cell division. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is an HDAC inhibitor that indirectly affects cell cycle regulation by modifying histone acetylation. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor that has demonstrated potential in research studies as an anticancer therapy by interfering with several cell cycle-related proteins. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine, also known as CYC202 or Seliciclib, is an experimental CDK inhibitor. It has been investigated for its potential use in cancer research. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is an experimental drug that inhibits various CDKs, including CDK4 and CDKIts mechanism of action holds promise for influencing cell cycle processes in cancer cells. | ||||||